Oral Carnitine for Cramps in Pregnancy
Oral L-Carnitine for the Treatment of Muscle Cramps in Pregnancy: A Randomized, Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90015
- USC Perinatal Group Medical Office
-
Los Angeles, California, United States, 90027
- USC Perinatal Group Medical Office
-
Los Angeles, California, United States, 90033
- Women's & Children's Hospital Midwife Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 16 or older
- Gestational Age 12 to 33 weeks
- Occurrence of muscle cramps at least once weekly
- Ability to tolerate oral L-Carnitine
- Ability / willingness to provide informed consent in English or Spanish
Exclusion Criteria:
- Prior treatment for muscle cramps during this pregnancy
- Chronic muscle cramps prior to pregnancy
- Magnesium administration beyond that contained in prenatal vitamins
- History of seizures
- History of Pre-term delivery before 36 weeks gestational age
- Inability to tolerate oral L-Carnitine (e.g. hyperemesis gravidarum)
- Inability or unwillingness to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: I
Oral L-Carnitine, 1g PO twice daily
|
L-Carnitine, 1g orally, twice daily
|
|
Placebo Comparator: II
Placebo, similar in appearance to experimental drug, given orally twice daily.
|
Placebo, similar in appearance to study tablets, given orally, twice daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Complete elimination of muscle cramps
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Emiliano R Chavira, MD,MPH, University of Southern California, Keck School of Medicine, Division of Maternal-Fetal Medicine
- Principal Investigator: Thomas M Goodwin, MD, University of Southern California, Keck School of Medicine, Division of Maternal-Fetal Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HS-06-00233
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.